The proposed Clover COVID-19 recombinant protein vaccine manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy) Working Group encourages members with experience in Benefit-Risk or recombinant protein technology to peer review this template by the end of the day Wednesday, July 17th, 2024.
Please provide feedback via this form >
The manuscript is as follows and is available for download. Should you want to provide comments within the document, please send your revised document to bc-coordinator@taskforce.org.
